Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licogliflozin dose-finding study in obesity
NCT03100058Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in obesity and Overweight (9 arms), sponsored by Novartis. Primary endpoint: Percent Change From Baseline in Body Weight at 24 weeks. Started May 2017; status: completed.
02
Drugs
licogliflozin
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03100058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100058.